Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ia, First in Human Open Label Dose Escalation Trial Evaluating Intravenous BI 1703880 in Combination With Intravenous Ezabenlimab for Treatment of Advanced Solid Tumours

NCT05471856 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT05471856
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05471856 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ia, First in Human Open Label Dose Escalation Trial Evaluating Intravenous BI 1703880 in Combination With Intravenous Ezabenlimab for Treatment of Advanced Solid Tumours
Lead sponsor
Boehringer Ingelheim
Phase
Phase 1
Overall status
Recruiting
Start date
February 24, 2023
Completion date
January 2, 2029
Enrollment
66 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors